D Weiss1, J J Kools, W R Taylor. 1. Division of Cardiology, Department of Medicine, Atlanta VA Medical Center and Emory University School of Medicine, Atlanta, GA 30322, USA.
Abstract
BACKGROUND: Angiotensin II may contribute to the development and progression of atherosclerotic lesions because of its growth and proinflammatory effects. We sought to determine whether angiotensin II-induced hypertension would augment and accelerate the development of atherosclerotic lesions in apoE-deficient mice. METHODS AND RESULTS: Angiotensin II (0.7 mg x kg(-1) x d(-1) SC) was administered to apoE-deficient mice via osmotic minipumps. The animals were placed on either standard chow or an atherogenic diet. After 8 weeks, the mean atherosclerotic lesion area in the descending thoracic and abdominal aortas of animals on a standard chow diet was 0.4+/-0.1% compared with 5.2+/-1.2% in those animals maintained on an atherogenic diet (P:<0.0001). In angiotensin II-treated animals on standard chow, the mean lesion area was increased to 11.0+/-2.3%, which was further increased to 69.9+/-9.4% (P:<0.0001) in angiotensin II-treated animals on an atherogenic diet. Similar findings were obtained when tissues from the ascending aorta were analyzed. At 8 weeks in mice receiving a standard chow diet, angiotensin II dramatically increased the atherosclerotic lesion area by 840+/-83 microm(2) (P:<0.0001). Animals on a high-fat diet had a similar marked increase in lesion area in response to angiotensin II (217+/-19 microm(2), P:<0.0001). In contrast, when hypertension was induced with norepinephrine, only a modest effect on the atherosclerotic lesion area was observed. CONCLUSIONS: Angiotensin II-induced hypertension specifically increased the development of atherosclerosis in apoE knockout mice. This response was seen in animals receiving either standard chow or an atherogenic diet. These studies demonstrate the profound effect of angiotensin II on the development of atherosclerosis.
BACKGROUND: Angiotensin II may contribute to the development and progression of atherosclerotic lesions because of its growth and proinflammatory effects. We sought to determine whether angiotensin II-induced hypertension would augment and accelerate the development of atherosclerotic lesions in apoE-deficient mice. METHODS AND RESULTS: Angiotensin II (0.7 mg x kg(-1) x d(-1) SC) was administered to apoE-deficient mice via osmotic minipumps. The animals were placed on either standard chow or an atherogenic diet. After 8 weeks, the mean atherosclerotic lesion area in the descending thoracic and abdominal aortas of animals on a standard chow diet was 0.4+/-0.1% compared with 5.2+/-1.2% in those animals maintained on an atherogenic diet (P:<0.0001). In angiotensin II-treated animals on standard chow, the mean lesion area was increased to 11.0+/-2.3%, which was further increased to 69.9+/-9.4% (P:<0.0001) in angiotensin II-treated animals on an atherogenic diet. Similar findings were obtained when tissues from the ascending aorta were analyzed. At 8 weeks in mice receiving a standard chow diet, angiotensin II dramatically increased the atherosclerotic lesion area by 840+/-83 microm(2) (P:<0.0001). Animals on a high-fat diet had a similar marked increase in lesion area in response to angiotensin II (217+/-19 microm(2), P:<0.0001). In contrast, when hypertension was induced with norepinephrine, only a modest effect on the atherosclerotic lesion area was observed. CONCLUSIONS: Angiotensin II-induced hypertension specifically increased the development of atherosclerosis in apoE knockout mice. This response was seen in animals receiving either standard chow or an atherogenic diet. These studies demonstrate the profound effect of angiotensin II on the development of atherosclerosis.
Authors: Frank M Davis; Debra L Rateri; Anju Balakrishnan; Deborah A Howatt; Dudley K Strickland; Selen C Muratoglu; Christopher M Haggerty; Brandon K Fornwalt; Lisa A Cassis; Alan Daugherty Journal: Arterioscler Thromb Vasc Biol Date: 2014-11-13 Impact factor: 8.311
Authors: Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas Journal: Pharmacol Rev Date: 2015-10 Impact factor: 25.468
Authors: Deborah D Chin; Christopher Poon; Noah Trac; Jonathan Wang; Jackson Cook; Johan Joo; Zhangjingyi Jiang; Naomi Sulit Sta Maria; Russell E Jacobs; Eun Ji Chung Journal: Adv Ther (Weinh) Date: 2020-02-03
Authors: Rima Elhage; Pierre Gourdy; Laurent Brouchet; Jacek Jawien; Marie-José Fouque; Catherine Fiévet; Xavier Huc; Yara Barreira; Jean Claude Couloumiers; Jean-François Arnal; Francis Bayard Journal: Am J Pathol Date: 2004-12 Impact factor: 4.307
Authors: Christa Caesar; Alicia N Lyle; Giji Joseph; Daiana Weiss; Fadi M F Alameddine; Bernard Lassègue; Kathy K Griendling; W Robert Taylor Journal: Cell Mol Bioeng Date: 2016-12-27 Impact factor: 2.321
Authors: Dennis Bruemmer; Alan R Collins; Grace Noh; Wei Wang; Mary Territo; Sarah Arias-Magallona; Michael C Fishbein; Florian Blaschke; Ulrich Kintscher; Kristof Graf; Ronald E Law; Willa A Hsueh Journal: J Clin Invest Date: 2003-11 Impact factor: 14.808
Authors: Tracy Henriques; Xuan Zhang; Frederique B Yiannikouris; Alan Daugherty; Lisa A Cassis Journal: Arterioscler Thromb Vasc Biol Date: 2008-05-01 Impact factor: 8.311